---
$id: https://graph.org.ai/products/commodity/51204102
$type: Product
source: UNSPSC
code: "51204102"
title: "Rilonacept"
class: "51204100"
classTitle: "Immunosupressant recombinant fusion proteins"
family: "51200000"
familyTitle: "Immunomodulating drugs"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Rilonacept

**UNSPSC Code**: 51204102
**Class**: [Immunosupressant recombinant fusion proteins](Immunosupressant recombinant fusion proteins.mdx)
**Family**: [Immunomodulating drugs](../Immunomodulating drugs.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes a biological response modifier with the molecular formula C9030H13932N2400O2670S74, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8K80YB5GMG, more generally known as rilonacept. European Medicines Agency schedules rilonacept in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB28994. The term RILONACEPT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21, No. 1, 2007, list 57. Most nations, for tariff and trade purposes, schedule Rilonacept under HS 30021020 and SITC 54163. SMILES:. As of Q4 2014, RILONACEPT remains US FDA's Preferred Term for this commodity. . Rilonacept bears US NLM identifiers UMLS ID C2343589 and NCI Concept Code C84137.

